2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-176411
    ONO-TR-772 2640847-32-9 98%
    ONO-TR-772 (VU6018042) is a selective TREK inhibitor (IC50: 15 nM). ONO-TR-772 enhances recognition memory in the MK-801-stimulated NOR mouse model. ONO-TR-772 can be used in the study of diseases related to cognitive impairment.
    ONO-TR-772
  • HY-176420
    VU6031545 98%
    VU6031545 is a potent mGlu 5 negative allosteric modulator with an IC50 of 15 nM. VU6031545 has excellent brain penetrant and oral bioavailability in rats.
    VU6031545
  • HY-176432
    BChE-IN-40 98%
    BChE-IN-40 (compound D40) is a potent butyrylcholinesterase inhibitor with an IC50 of 0.59 μM. BChE-IN-40 exhibits strong anti-inflammatory effects with an IC50 of 4.55 μM for nitric oxide suppression. BChE-IN-40 demonstrates excellent blood-brain barrier permeability.
    BChE-IN-40
  • HY-176434
    DDL-218 2767324-34-3
    DDL-218 is an orally active and potent SirT1 inhibitor. DDL-218 enhances SirT1 in ApoE4-expressing neurons and a murine AD model. DDL-218 can be used in the study of Alzheimer's disease.
    DDL-218
  • HY-176438
    DDL-357 3077900-08-1 98%
    DDL-357 is a potent secreted clusterin enhancer. DDL-357 reduces phospho-tau in brain and improves memory in the murine 3xTg-AD model.
    DDL-357
  • HY-176439
    AChE-IN-88 2758789-03-4 98%
    AChE-IN-88 (Compound 26) is a novel pyridazine derivative. AChE-IN-88 is an orally active multi-target ligand for Alzheimer's disease (AD) that inhibits both acetylcholinesterase (AChE) and amyloid β protein (Aβ) aggregation (pIC50: 7.16).
    AChE-IN-88
  • HY-176487
    SARM1-IN-6 3080315-51-8
    SARM1-IN-6 (Compound 17a) is a brain-permeable SARM1 orthosteric inhibitor with IC50 of 14 nM for NAM and 74 nM for HEK cells.
    SARM1-IN-6
  • HY-176705
    AAK1-IN-9 98%
    AAK1-IN-9 (Compound 3) is an AAK1 (adaptor associated kinase 1) inhibitor with an IC50 of 10.92 nM. AAK1-IN-9 can be used in the study of neurodegenerative diseases.
    AAK1-IN-9
  • HY-176706
    AAK1-IN-10 3083494-45-2 98%
    AAK1-IN-10 (Compound 1-2) is an AAK1 inhibitor. AAK1-IN-10 has significant AAK1 enzyme inhibitory activity (IC50: 9.62 nM). AAK1-IN-10 mainly exerts its effects by inhibiting the activity of connexin-associated kinase 1 (AAK1). AAK1-IN-10 has low cardiotoxicity (IC50 = 13.7 μM). AAK1-IN-10 can be used in the study of diabetic neuropathy and postherpetic pain.
    AAK1-IN-10
  • HY-176715
    Kv7.2 activator-1 2981435-59-8
    Kv7.2 activator-1 (Compound 8) is a Kv7.2/3 activator with an EC50 of 178 nM. Kv7.2 activator-1 has a long half-life of 120 minutes in HLM.
    Kv7.2 activator-1
  • HY-176717
    5-HT1AR agonist 3 2410053-55-1
    5-HT1AR agonist 3 (Compound 77) is a 5-HT1A agonist. 5-HT1AR agonist 3 has 5-HT1A receptor agonist activity (EC50: 1.3 nM). 5-HT1AR agonist 3 mainly exerts its effects by activating 5-HT1A receptors and can be used in the study of neuropsychiatric diseases such as anxiety, depression and sleep disorders.
    5-HT1AR agonist 3
  • HY-176721
    5-HT2A receptor agonist-10 3031053-17-2
    5-HT2A receptor agonist-10 (Compound (R)-I-121.HCl) is a 5-HT2A receptor agonist, with an IC50 of 2192.39 nM for h5-HT2A and h5-HT1A, respectively. 5-HT2A receptor agonist-10 can be used for the research of psychosis, mental illnesses and CNS disorders.
    5-HT2A receptor agonist-10
  • HY-176731
    MSK-9
    MSK-9 is a positive allosteric modulator of the P2X4 receptor with dual activities of enhancing ion conductance and delaying receptor inactivation. MSK-9 stabilizes the open state of the P2X4 receptor through rigid 3-piperidinyl and hydrophobic menthyl substituents. MSK-9 can be used in the study of multiple sclerosis (MS).
    MSK-9
  • HY-176733
    HDAC6-IN-61
    HDAC6-IN-61 (Compound 4e) is a HDAC6 inhibitor (IC50: 73 nM) with selectivity over other HDAC isoforms. HDAC6-IN-61 is also a GPR40 activator. HDAC6-IN-61 increases acetylated tubulin and ERK phosphorylation levels. HDAC6-IN-61 can be used for research of neuroinflammation such as Alzheimer's disease.
    HDAC6-IN-61
  • HY-18295A
    rel-Erteberel 533883-77-1 98%
    rel-Erteberel is rel isomer of Erteberel (HY-18295). Erteberel is a potent and selective estrogen receptor beta (ERβ) agonist with Ki and EC50 of 1.54 nM and 3.61 nM, respectively. Erteberel has anti-tumor activities.
    rel-Erteberel
  • HY-18663A
    CP-465022 maleate 199656-46-7 98%
    CP-465022 Maleate is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC50 of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes.
    CP-465022 maleate
  • HY-18663B
    CP-465022 hydrochloride 1785666-59-2 98%
    CP-465022 hydrochloride is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC50 of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes.
    CP-465022 hydrochloride
  • HY-18981R
    Decursin (Standard) 5928-25-6
    Decursin (Standard) is the analytical standard of Decursin. This product is intended for research and analytical applications. Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities[4].
    Decursin (Standard)
  • HY-19225A
    Ensaculin free base 155773-59-4 98%
    Ensaculin free base (KA-672) is a NMDA antagonist and have high affinities to serotonergic 5-HT1A and 5-HT7 receptors, adrenergic α1, and dopaminergic D2 and D3 receptors. Ensaculin free base is a memory-enhancing agent. Ensaculin free base has the potential as an antidementia agent acting on various transmitter systems.
    Ensaculin free base
  • HY-19358A
    2-Methyl-5-HT hydrochloride 845861-49-6 98%
    2-Methyl-5-HT hydrochloride (2-Methyl-5-hydroxytryptamine hydrochloride) is a potent and selective 5-HT3 receptor agonist. 2-Methyl-5-HT hydrochloride is shown to display anti-depressive-like effects.
    2-Methyl-5-HT hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity